Feasibility of the enhanced neuromuscular blockade recovery protocol with selective use of sugammadex in thyroid surgery with intraoperative neuromonitoring

IF 2.3 3区 医学 Q1 OTORHINOLARYNGOLOGY Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2024-06-15 DOI:10.1002/hed.27826
Shuwen Yang MD, Zhirong Sun MD, Changming Zhou PhD, Wenjun Wei MD, Ning Qu MD, Rongliang Shi MD, Ben Ma MD, Weibo Xu MD, Qinhai Ji MD, Jun Zhang MD, Yu Wang MD, PhD
{"title":"Feasibility of the enhanced neuromuscular blockade recovery protocol with selective use of sugammadex in thyroid surgery with intraoperative neuromonitoring","authors":"Shuwen Yang MD,&nbsp;Zhirong Sun MD,&nbsp;Changming Zhou PhD,&nbsp;Wenjun Wei MD,&nbsp;Ning Qu MD,&nbsp;Rongliang Shi MD,&nbsp;Ben Ma MD,&nbsp;Weibo Xu MD,&nbsp;Qinhai Ji MD,&nbsp;Jun Zhang MD,&nbsp;Yu Wang MD, PhD","doi":"10.1002/hed.27826","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>To investigate feasibility of utilizing enhanced neuromuscular blocking agents with selective recovery protocol during thyroid surgery with intraoperative neuromonitoring (IONM).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Two-hundred and ninety patients were randomized into two groups: group A 0.3 mg/kg rocuronium and group B 0.6 mg/kg. Sugammadex 2 mg/kg was injected if needed followed initial vagal stimulation (V0). Electromyography signals from vagus and recurrent laryngeal nerves before and after resection were recorded as V1, V2, R1, and R2.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In group B, 30 patients (20.7%) had V0 signals &lt;100 μV, compared to 9 (6.2%) in group A. After sugammadex administration, 144 patients (99.3%) in both groups achieved positive V1 signals. Group B demonstrated a shorter surgical time from rocuronium injection to V2 stimulation compared to group A, accompanied by a significantly lower incidence of intraoperative body movement (0 vs. 16 patients).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>0.6 mg/kg rocuronium with selective use 2 mg/kg sugammadex for IONM in thyroid surgery can meet both anesthesia and surgery demands.</p>\n </section>\n </div>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":"46 12","pages":"2917-2925"},"PeriodicalIF":2.3000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hed.27826","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

To investigate feasibility of utilizing enhanced neuromuscular blocking agents with selective recovery protocol during thyroid surgery with intraoperative neuromonitoring (IONM).

Methods

Two-hundred and ninety patients were randomized into two groups: group A 0.3 mg/kg rocuronium and group B 0.6 mg/kg. Sugammadex 2 mg/kg was injected if needed followed initial vagal stimulation (V0). Electromyography signals from vagus and recurrent laryngeal nerves before and after resection were recorded as V1, V2, R1, and R2.

Results

In group B, 30 patients (20.7%) had V0 signals <100 μV, compared to 9 (6.2%) in group A. After sugammadex administration, 144 patients (99.3%) in both groups achieved positive V1 signals. Group B demonstrated a shorter surgical time from rocuronium injection to V2 stimulation compared to group A, accompanied by a significantly lower incidence of intraoperative body movement (0 vs. 16 patients).

Conclusions

0.6 mg/kg rocuronium with selective use 2 mg/kg sugammadex for IONM in thyroid surgery can meet both anesthesia and surgery demands.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在甲状腺手术中选择性使用苏加麦克斯的神经肌肉阻滞恢复强化方案与术中神经监测的可行性。
背景:研究在甲状腺手术中使用增强型神经肌肉阻断剂和选择性恢复方案并配合术中神经监测(IONM)的可行性:研究在甲状腺手术中使用增强型神经肌肉阻滞剂并配合术中神经监测(IONM)选择性恢复方案的可行性:将290名患者随机分为两组:A组0.3毫克/千克罗库溴铵,B组0.6毫克/千克。在初始迷走神经刺激(V0)后,根据需要注射 2 毫克/千克舒格迈司。切除前后迷走神经和喉返神经的肌电图信号分别记录为 V1、V2、R1 和 R2:结果:在 B 组中,30 名患者(20.7%)出现 V0 信号:在甲状腺手术中使用0.6 mg/kg 罗库溴铵并选择性使用2 mg/kg 苏加麦克斯进行离子导入,可以同时满足麻醉和手术的要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.00
自引率
6.90%
发文量
278
审稿时长
1.6 months
期刊介绍: Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.
期刊最新文献
Pectoral-Sparing Deltoid Artery Use in the Vessel-Depleted Neck: A Pictorial Essay. Safety and Efficacy of Intra-Arterial Chemotherapy Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma. Bitter Taste Receptor Agonists Induce Apoptosis in Papillary Thyroid Cancer. Sinonasal NUT Carcinoma: A Systematic Review With Pooled Analysis and Report of a Case of Extraordinary Survival. Combined Tumor Infiltrating Lymphocytes and PD-L1 Status in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1